InfuSystem Holdings, Inc. (NYSE:INFU - Get Free Report)'s share price crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $13.02 and traded as low as $12.34. InfuSystem shares last traded at $12.80, with a volume of 249,425 shares.
Wall Street Analyst Weigh In
Separately, B. Riley Financial reiterated a "buy" rating and set a $20.00 price target (up from $12.00) on shares of InfuSystem in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $17.50.
Check Out Our Latest Analysis on InfuSystem
InfuSystem Stock Down 7.5%
The stock has a market cap of $258.33 million, a PE ratio of 213.37 and a beta of 1.49. The firm has a fifty day moving average of $13.02 and a 200 day moving average of $10.36. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50.
Institutional Investors Weigh In On InfuSystem
Several hedge funds and other institutional investors have recently made changes to their positions in the business. AXQ Capital LP purchased a new stake in InfuSystem during the second quarter worth approximately $98,000. Commerce Bank acquired a new position in InfuSystem in the second quarter valued at approximately $121,000. Bank of America Corp DE purchased a new position in InfuSystem in the second quarter valued at approximately $132,000. GK Wealth Management LLC purchased a new position in InfuSystem in the second quarter valued at approximately $133,000. Finally, Deutsche Bank AG acquired a new stake in InfuSystem during the second quarter worth approximately $185,000. Institutional investors and hedge funds own 71.13% of the company's stock.
About InfuSystem
(
Get Free Report)
InfuSystem Holdings, Inc is a health care services company that provides ambulatory infusion pump and related clinical support services. The company helps health care providers and patients manage therapies outside traditional hospital settings, with a particular focus on oncology and other treatments requiring portable infusion equipment.
Its services include the rental and management of infusion pumps, equipment maintenance and biomedical services, delivery of related supplies, patient education, and 24-hour clinical and technical support.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InfuSystem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InfuSystem wasn't on the list.
While InfuSystem currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.